Part 7/14:
A disturbing trend lies in the funding and research surrounding these weight-loss medications. Novo Nordisk finances studies at prestigious institutions like Harvard, raising alarms about conflicts of interest—i.e., the very company profiting from the drug funding the research on obesity. The intertwining of corporate interests and medical research blurs ethical lines, suggesting that the narrative around obesity and its treatment is heavily influenced by private sector agendas.